Immune-checkpoint blockade—durable cancer control
EI Buchbinder, FS Hodi - Nature reviews Clinical oncology, 2016 - nature.com
EI Buchbinder, FS Hodi
Nature reviews Clinical oncology, 2016•nature.comIn 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with
phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy.
Understanding the mechanisms involved in an effective antitumour immune response are
now key to further advances. Several studies published in 2015 have increased our
understanding of the complex relationships that exist between our immune system and
malignancy.
phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy.
Understanding the mechanisms involved in an effective antitumour immune response are
now key to further advances. Several studies published in 2015 have increased our
understanding of the complex relationships that exist between our immune system and
malignancy.
In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immune response are now key to further advances. Several studies published in 2015 have increased our understanding of the complex relationships that exist between our immune system and malignancy.
nature.com